NDLI: Safety of omalizumab in asthma.

Please wait, while we are loading the content...

Year: 2017 Volume: 16

Year: 2016 Volume: 15

Year: 2015 Volume: 14

Year: 2014 Volume: 13

Year: 2013 Volume: 12

Year: 2012 Volume: 11

Year: 2011 Volume: 10

Year: 2011 Volume: 10 Issue: 6

Year: 2011 Volume: 10 Issue: 5

Year: 2011 Volume: 10 Issue: 4

Year: 2011 Volume: 10 Issue: 3

Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence.

From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.

Pegylated-interferon- (2a) in clinical practice: how to manage patients suffering from side effects.

Drug safety evaluation of ziprasidone.

Statin-induced myopathy: a review and update.

The safety of thiazolidinediones.

Safety of omalizumab in asthma.

The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen.

Use of the self-controlled case series method in drug safety assessment.

A pooled analysis of 20 post-authorization surveys of olmesartan involving 156,682 hypertensive patients.

Immune alterations in untreated and treated myelodysplastic syndrome.

Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Safety review of combination drugs for hyperlipidemia.

Drug safety evaluation of exemestane.

The safety of atypical antipsychotics: does QTc provide all the answers?

Year: 2011 Volume: 10 Issue: 2

Year: 2011 Volume: 10 Issue: 1

Year: 2010 Volume: 9

Year: 2009 Volume: 8

Year: 2008 Volume: 7

Safety of omalizumab in asthma.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Tan, Ricardo A. Corren, Jonathan
Description	Country affiliation: United States Author Affiliation: Tan RA ( California Allergy and Asthma Medical Group, 11645 Wilshire Blvd., Suite 1155, Los Angeles, CA 90025, USA. rtantan@aol.com)
Abstract	INTRODUCTION: Omalizumab is the first mAb to be introduced for the management of asthma. It is also the first agent designed to block the effects of IgE in initiating the allergic cascade resulting in asthma manifestations. Introduced in 2003, it is now widely used as an effective therapeutic tool in moderate-to-severe allergic asthmatics who are uncontrolled on maximal conventional therapy, including high-dose inhaled steroids and long-acting ß-agonists. There is still understandable concern regarding the long-term effects of this drug. AREAS COVERED: The authors provide a review of safety data generated by controlled clinical trials and post-marketing surveillance as well as a brief overview of the clinical indications and efficacy of omalizumab. They also address specific issues of concern, including the risk of anaphylaxis and malignancy. The reader will gain a working knowledge of the role of omalizumab in current guidelines for the management of asthma. EXPERT OPINION: Omalizumab appears to be safe and well-tolerated. The possible association of malignancy with omalizumab has been of the greatest concern to patients and physicians. Analysis of clinical study data shows that this incidence is rare and the relative risk of cancer with omalizumab is not significantly different from that which is expected in the general population of people with asthma. As part of a relatively new class of agents, continued surveillance is needed as its indications expand and its use in the population continues to grow.
File Format	HTM / HTML
ISSN	14740338
Issue Number	3
Volume Number	10
e-ISSN	1744764X
Journal	Expert Opinion on Drug Safety
Language	English
Publisher	Taylor & Francis
Publisher Date	2011-05-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Anti-asthmatic Agents Adverse Effects Therapeutic Use Antibodies, Anti-idiotypic Antibodies, Monoclonal Asthma Drug Therapy Animals Pharmacology Antibodies, Monoclonal, Humanized Humans Omalizumab Randomized Controlled Trials As Topic Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in